Perioperative Anaesthetic Management of Confirmed or Suspected COVID-19 Patients

Emre Erbabacan, Aylin Özülek, Çiğdem Akyol Beyoğlu, Fatiş Altındaş
Department of Anaesthesiology and Reanimation, Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey

Cite this article as: Erbabacan E, Özülek A, Akyol Beyoğlu Ç, Altındaş F. Perioperative Anaesthetic Management of Confirmed or Suspected COVID-19 Patients. Turk J Anaesthesiol Reanim 2020; 48(3): 180-7.

Abstract

The outbreak of coronavirus disease (COVID-19) that started in Wuhan, China, has spread to 210 countries, infecting 2,726,274 patients and causing 191,075 deaths by April 24, 2020, and has turned into a global threat. Although various measures have been taken to stop human-to-human transmission in many countries, health care workers are in the high-risk zone for transmission as they deliver patient care. It is evident that anaesthesiologists will keep encountering patients with confirmed or suspected COVID-19 infection who will undergo emergency surgeries. Anaesthesiologists carry a higher risk of being infected during aerosol-creating procedures, hence appropriate protective measures should be taken, both during preoperative evaluation and management anaesthesia. Anaesthesia management of patients with COVID-19 also is a challenge for anaesthesiologists as it is an infection that may affect not only the respiratory system but also other vital organs. The aims of this review are to provide prudent safety measures to protect anaesthesiologists and other health care workers in the operating theatre and recommendations for the safest anaesthesia management of patients with suspected or confirmed COVID-19 undergoing surgery.

Keywords: Anaesthesia management, COVID-19, safety

Introduction

The outbreak of coronavirus disease (COVID-19) became a global threat. Although not as deadly as other severe acute respiratory diseases (SARS) outbreaks like the SARS of 2003 and Middle East Respiratory Syndrome (MERS) of 2012, one person carrying the virus can infect up to 5.7 people whereas with MERS, the number of ‘R0’ (reproductive number; a mathematical term used to define how contagious an infectious disease is) is 0.45 person only [1]. The spread of COVID-19 may increase further as it has a longer asymptomatic period that can prolong up to 14 days in some cases [2]. Anaesthesiologists carry a higher risk during aerosol-creating procedures, such as tracheal intubation, mask ventilation, extubation, tracheostomy, or bronchoscopy, as the transmission greatly increases with exposure to droplets as well as direct contact with secretions [3, 4].

Although elective surgeries in most centres were ceased and many surgeries postponed or cancelled, emergency and oncological surgeries are still performed in many centres as in our hospital. Hence, considering that elective surgeries will also eventually commence, safe medical practices and protocols to prevent transmission to anaesthesiologists must be established. Anaesthesia management of patients with COVID-19 is a challenge for anaesthesiologists as it is an infection that may affect not only the respiratory system but also other vital organs of the patient.

The aims of this review are to provide recommendations to protect anaesthesiologists and other health care workers in the operating theatre and for the safe anaesthesia management of patients with suspected or confirmed COVID-19 undergoing surgery.

Preoperative Evaluation and Preparation

Although the first symptom of COVID-19 infection is usually a fever and dry cough, other non-significant symptoms such as fatigue, diarrhoea, and mild myalgia are also recorded [5]. In addition, the number of asymptomatic
cases who are still infectious is projected to be around 50%, complicating the perioperative period (6). Ten percent of the patients in the ICU are in dire need of mechanical ventilation owing to respiratory distress, sepsis, and multiple organ dysfunction. Severe hypoxaemia is observed usually following the 7th day of the start of the symptoms (7). The radiographic imaging is specific, especially for computerised tomography, usually with multiple small hand film shadows and interstitial changes in the sub-pleural and peripheral areas that advance into ground-glass opacity and consolidations in both lungs; however, pleural effusion is rare (8).

As in most viral diseases, white blood cells decrease with an increase in neutrophils and a more evident decrease in lymphocytes in COVID-19 patients. There are studies showing mild increases in aspartate and alanine amino transferase (AST and ALT), total bilirubin, cardiac troponin levels, and a decrease in albumin (9).

Most patients with COVID-19 have high Factor VIII levels and prolonged activated partial thromboplastin time but normal prothrombin time. Increased D-dimer levels, prothrombin time, and thrombocytopenia are predictive of adverse outcome and a possible disseminated intravascular coagulation that can escalate the blood loss during surgery (10, 11).

Thromboembolic events are not rare in COVID-19 patients, including pulmonary embolism and cerebrovascular events probably because of both platelet activation and endothelial dysfunction (10, 12).

There are studies showing acute kidney disease is high in patients with COVID-19 (13) and conclude that this is probably due to the direct cytopathic effect of the virus on kidneys. Elevated creatinine and blood urea nitrogen (BUN) levels are associated with higher mortality and morbidity (13). However, other studies showed only a mild increase in creatinine and BUN, which returned to normal levels without any therapy (14). Regardless, avoiding the use of nephrotoxic drugs and close follow-up of the creatinine levels are essential.

Patients with COVID-19 use antipyretics, antivirals, and other drugs. These drugs may affect liver and pancreas functions and increase ALT, AST, and gamma-glutamyl transferase (GGT) (15). The pre-evaluation of increases in laboratory values is important in terms of selecting the drugs that will be used for anaesthesia.

Several drugs such as chloroquine, hydroxychloroquine, atazanavir, lopinavir/ritonavir, remdesivir, favipiravir, ribavirin, azithromycin, tocilizumab, and interferon beta are used for the experimental treatment of COVID-19 for their potential benefits. Some of these drugs can interact with anaesthetics such as propofol, sevoflurane, and tramadol. Co-administration of lopinavir/ritonavir, chloroquine, hydroxychloroquine, azithromycin, and dexamethasone with these anaesthetics can cause cardiac arrhythmias; hence, the patients should be monitored very closely (16). Atazanavir and lopinavir/ritonavir can potentiate the effects of bupivacaine, ketamine, rocuronium, fentanyl, metamizol, tramadol, and pethidine (16). Tocilizumab can decrease the effects of bupivacaine, ketamine, fentanyl, and oxycodone (16). Favipiravir can increase the effect of paracetamol (16). Cisatracurium, succinylcholine, desflurane, isoflurane, nitrous oxide, remifentanil, ephedrine, diclofenac, ibuprofen, and naproxen can be used safely with no significant interactions with the COVID-19 therapies mentioned above (16).

Usually, surgeons or emergency physicians are the first clinicians to inspect and record the medical history and order radiological and laboratory tests. To decrease human traffic and decrease cross contamination, it is suggested that anaesthesiologists, surgeons, infectious disease, and emergency physicians should create a protocol for the preoperative evaluation (7). First responders should be informed by the anaesthesiologist of any additional test that might be needed in specific patients, such as arterial blood gas analysis, C-reactive protein, and procalcitonin levels.

All patients admitted to the operation room should be considered infected with COVID-19 as the rate of asymptomatic patients is high. Although all patients should be screened with PCR testing prior to surgery, this might not be possible in many hospitals, and the false negativity of the test may be as high as 30% (17). Chest CT is shown to be more sensitive to diagnose COVID-19 infection and suggested as a primary
method to detect the disease in epidemic areas, but it is not feasible in all patients and the radiation risk should be taken into account (18).

As mentioned before, according to the protocol between surgeons and anaesthesiologists, the information about the history and test results of the patient is already known to the anaesthesiologists, which will enable them to spend minimum face-to-face time with the patient. Thorough airway evaluation is essential even though strict infection control measures can complicate a complete examination. The protective gowns, eye protection, and other personal protective equipment (PPE) for safety may further compromise intubation. Thus, every patient should be considered to have a difficult airway.

Hypoxaemia can be evident in some patients. If the surgery cannot be postponed until the patient can be stabilised, follow-up in the intensive care unit may be necessary. As thrombocytopenia is a symptom observed in severe patients, platelet levels should be checked before the operation and if needed, thrombocyte suspensions and other blood products must be prepared (11).

Even in patients with no cardiac history, COVID-19 can present itself with cardiac arrhythmias. Furthermore, azithromycin and hydroxychloroquine used in the COVID-19 treatment, as well as anaesthetics such as propofol, sevoflurane, and tramadol, may prolong the QT interval, leading to arrhythmias in the patient (16).

In addition to routine informed consent, patients must be informed of the particular additional risks of COVID-19 such as severe respiratory disease, kidney injury, and thromboembolic events. Patients with no symptoms or negative tests should also be informed about the possibility of an infection or cross-contamination although they are operated upon in another non-COVID-19 operating theatre.

Patients with suspected or confirmed COVID-19 that are going to be operated upon should be operated in a COVID-positive operation room with negative pressure. Clear and visible marking of the contaminated areas is crucial. It is essential that patients should be transferred via the shortest and the least crowded pre-designated route to decrease the number of workers coming in contact with the patient. Staff segregation and limiting the operation theatre staff are also important in terms of cross-contamination (19). The patient should also wear a facemask during transport and in the operating theatre.

During the preoperative evaluation, protective measures should be taken carefully with personal protection equipment (PPE) used as needed. If the patient is a suspected or a confirmed case, N95 respirators, eye protection, a disposable surgical cap, gowns, and double gloves should be worn. If no aerosol-producing examination is planned, non-sterile, disposable isolation gowns would be sufficient; however, surgical gowns known as the Association of the Advancement of Medical Instrumentation (AMII) Level III gowns should be worn when an aerosol- or blood-producing intervention is probable (20).

**Intraoperative Period**

Although for many emergency or oncological surgeries, general anaesthesia is recommended, regional anaesthesia should be preferred over general anaesthesia whenever possible in order to minimise aerosol-generating procedures such as intubation and extubation (21). Both neuraxial anaesthesia and peripheral nerve blocks are not considered aerosol-generating procedures. Regional anaesthesia also reduces postoperative pulmonary complications, which can complicate the respiratory failure in a COVID-19 infection further. Necessary care must be taken to perform the surgery completely under regional anaesthesia and prevent transition to general anaesthesia. To prevent this transition, location, duration of surgery, and local anaesthetic dose to be used should be taken into consideration, and open communication with the surgeon is essential. It would be preferable to start with a planned general anaesthesia rather than converting to general anaesthesia during surgery when regional anaesthesia is not sufficient as risk of transmission increases with emergency or unplanned interventions. Regional anaesthesia interventions should be performed in a negative pressure operating theatre by the most experienced anaesthesiologist.

Currently, routine indications and contraindications for regional anaesthesia also apply for Covid-19-positive patients. The contraindications such as bleeding disorders must be taken into account as it is a common finding mainly in severe COVID-19 patients (22). Platelet count should be monitored before neuraxial block administration (23).

Standard monitoring suggested by the European Society of Anaesthesiology (ESA) should be used for all patients. Disposable plastic sheets can be used to wrap the screens of the monitors and most sections of the anaesthesia machines to decrease the risk of contamination by touching (20). Deep sedation should be avoided in order to reduce the need for airway manipulations (23).

During regional anaesthesia, patients should wear surgical mask at all times even when they are receiving supplementary oxygen therapy. Self-protection of the anaesthesiologist is immensely important, and he or she must be wearing N95 respirators during the regional anaesthesia intervention.
Zhong et al. (21) showed that N95 masks are safer both for the anaesthesiologists and the patients compared to surgical masks while performing spinal anaesthesia on patients with COVID-19.

Routine aseptic techniques should be complied within neuraxial anaesthesia and peripheral block applications. Since Covid-19 virus remains viable on plastic material for a longer period of time, paper drapes should be preferred instead of plastic (24). Since virus is isolated from the cerebrospinal fluid (CSF) of patients with Covid-19 encephalitis, free flow of CSF should not be allowed during lumbar puncture (25).

Peripheral nerve blocks may be favoured over neuraxial blocks as they are safer in terms of thrombocytopenia and hypotension. For upper extremity surgeries, peripheral nerve blocks that affect the diaphragm and additional respiratory muscles should not be preferred so as to prevent respiratory depression (23), i.e., infraclavicular block or axillary block should be selected instead of supraclavicular or interscalene blocks, which can lead to phrenic nerve paralysis. At present, no suggestions are made to adjust the local anaesthetic dose in spinal anaesthesia in any patient group; however, adjuvant opioid use is not advocated (23).

Normally, execution of peripheral nerve blocks and the onset of action can be relatively time consuming. This can be considered a disadvantage compared to other anaesthesia techniques. Nevertheless, when performed by a skilled anaesthesiologist and ultrasound-guided techniques, the time needed for block performing will decrease.

Neuraxial anaesthesia is shown to be safe for Caesarean delivery in COVID-19 patients and is still the first choice of anaesthesia (26).

If general anaesthesia is indicated, rapid sequence intubation (RSI) is recommended in order to minimise the spread of aerosols. A senior anaesthesiologist should perform the intubation. The logic behind this recommendation is to shorten the duration and avoid multiple attempts of intubation. With PPE and other barriers that will be discussed later, such as plastic sheets or aerosol box, even the easiest ventilation and intubation can be hard to achieve as those measures create a reasonable ineptness in controlling the laryngoscope and endobronchial tube. Video laryngoscopes are advocated as it will both decrease the duration of the procedure and increase the distance of the anaesthesiologist from the airway. Capnography may be preferred over auscultation to confirm a successful intubation; however, auscultation should be performed to ensure bilateral equal ventilation (4). Tracheal tube cuff should be inflated immediately after intubation to seal the airway, and then ventilation may be started (4). Cuffs should be inflated until the pressure is 5 cmH$_2$O over plateau pressure to disable any leaks. The second generation supraglottic airway devices may be used for unanticipated difficult airway (4). Patients with predicted difficult airway should be evaluated individually. Usually, awake fibroptic intubation is not recommended because of the high risk of aerosol generation but can be used if that is the best choice for the patient.

Preoxygenation is important before RSI. Using a well-fitting face mask, that does not allow any leaks, prevents the aerosols from scattering and hence is safer. Preoxygenation should be done with 100% oxygen at least for 5 minutes. Another method for preoxygenation that the patients may benefit from is the use of high flow nasal oxygen (HFNO) therapy to avoid desaturation during RSI (27). Contrary to popular belief, it has been shown that both oxygenation with masks and HFNO therapy share a similar risk in terms of aerosol generation (28). Novel methods are developed to protect the staff from the aerosolisation of the laryngoscopy. A see-through polycarbonate cube covering the patient’s head and upper torso with two holes opened to allow the anaesthesiologist to reach through and perform the intubation by a video laryngoscope has been reported and used by many anaesthesiologists (Figure 1). The plans for the ‘aerosol box’ have been released by Hsien Yung Lai (29). Another method described is using sec-

![Figure 1. Intubation with aerosol box](image-url)
through plastic covers and performing ventilation and intubation under it (Figure 2). These techniques are successful in containing aerosols; however, further complicates the performance of ventilation and intubation. However, if the patients are already hypoxaemic and cannot tolerate apnoea during RSI, they should be ventilated by the mask using either aerosol box or plastic covers to contain the aerosol generation.

‘Heat and moisture exchanger filters’ (HMEF) and ‘high-efficiency particulate absorbing (HEPA) filters’ must be used between the circuit and the mask during ventilation. Using one of those filters attached to the intubation tube’s proximal end will stop aerosols from creating turbulence through the intubation tube and scatter around. Using filters on both inspiration and expiration port of the respiratory circuit may protect the anaesthesia machine from viral contamination (30).

Using a closed anaesthesia circuit and a closed airway suction system is recommended (7). If it is not possible to minimise the number of essential suctions, the ventilator must be always paused before any airway disconnections (7).

In addition to using routine drugs (2 mg kg\(^{-1}\) propofol, 1 mg kg\(^{-1}\) rocuronium) in RSI, it is suggested that administration of intravenous lidocaine (1.5 mg kg\(^{-1}\)) before intubation and extubation can effectively reduce coughing (31). To suppress coughing related to opioids such as fentanyl, it is suggested that they should be given following induction but before intubation. Ensuring that the patient has full muscle relaxation is also essential as bucking due to incomplete relaxation can cause aerosolisation.

Following intubation, gloves should be taken off and a new pair should be worn. Each time contact with a secretion occurs, gloves must be changed before they contaminate the environment and hands disinfected.

The electrocautery must be in the lowest possible setting to reduce the surgical smoke, which may be a source of aerosolisation and infection as shown in studies for other viral infections (20, 32).

As viral RNA is traced in the plasma of 15% of the patients, transmission via transfusion is a possibility (30). This might be a problem in non-COVID or suspected patients undergoing surgery. Studies are needed to show the safety of transfusion, but precautions must be taken, especially by screening the blood donors’ history of symptoms, such as fever, cough, and suspicious contact with infected patients (33). Transfusion must be retained if possible, using other blood salvaging methods.

An unanticipated finding of COVID-19 pneumonia is severe hypoxaemia accompanying normal or mildly decreased compliance (34). Although mild cases of COVID-19 do not show any sign of hypoxemia, severe cases fulfil the Berlin Criteria for acute respiratory distress syndrome (ARDS). As in all ARDS cases, lung-protective ventilation strategies should be followed to decrease ventilator induced injury (35). The use of low tidal volume (4-6 mL kg\(^{-1}\) of predicted body weight) and limiting plateau pressure under 30 cmH\(_2\)O with the lowest possible PEEP settings is recommended (36). In mild cases, inhalation anaesthetics can be used to manage anaesthesia. However, in severe cases, as severe hypoxemia in compliant lungs is explained with the loss of hypoxic vasoconstriction, the use of total intravenous anaesthesia may be preferred (34).

There is no direct data concerning fluid therapy for COVID-19 patients. Restricted fluid strategy is recommended based on studies concerning sepsis and ARDS by Surviving Sepsis Campaign Guideline (36). Balanced crystalloids should be chosen over colloids (36). Norepinephrine and vasopressin can be used as vasoactive agents in shock (36). Serum lactate, skin temperature, and urine output should be monitored for adequate fluid administration for every patient individually.

Inadvertent perioperative hypothermia should be prevented. Body temperature of the patient should be monitored. The safest method to measure body temperature is using dispos-
The authors declared that this study has received no financial support. The authors have no conflicts of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

References

1. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis 2020; 26: DOI: 10.3201/eid2607.200282. [Crossref]
2. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577-82. [Crossref]

3. Chan JF, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395: 514-23. [Crossref]

4. Cook TM, El-Boghdady K, McGuire B, McNarry AE, Patel A, Higgs A. Consensus Guidelines for Managing the Airway in Patients With COVID-19: Guidelines From the Difficult Airway Society, the Association of Anaesthetists the Intensive Care Society, the Faculty of Intensive Care Medicine and the Royal College of Anaesthetists. Anaesthesia 2020; 75: 785-99. [Crossref]

5. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-9. [Crossref]

6. Nishiura H, Kobayashi T, Suzuki A, Jung S-Mok, Hayashi K, Kinoshita R, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 2020; 94: 154-5. [Crossref]

7. Chen X, Liu Y, Gong Y, Guo X, Zuo M, Li J, et al. Perioperative Management of Patients Infected With the Novel Coronavirus: Recommendation From the Joint Task Force of the Chinese Society of Anesthesiology and the Chinese Association of Anesthesiologists. Anesthesiology 2020; 132: 1307-16. [Crossref]

8. Hosseiny M, Kooraki S, Gholamrezanezhad A, Reddy S, Myers L. Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome. Am J Roentgenol 2020; 214: 1078-82. [Crossref]

9. Lipişi G, Plebani M. Laboratory abnormalities in patients with COVID-19 infection. Clin Chem Lab Med 2020; DOI: 10.1515/clinchem-2020-0198. [Crossref]

10. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol 2020; 1-4. [Crossref]

11. Lipişi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020; 506: 145-8. [Crossref]

12. Beun R, Kusadasi N, Sikma M, Westerink J, Huiskes R. Neurological complications of a family cluster. Lancet 2020; 395: 514-23. [Crossref]

13. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97: 829-38. [Crossref]

14. Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol 2020; 1-6. [Crossref]

15. Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol 2020; 8: 18-24. [Crossref]

16. Liverpool Drug Interactions Group. University of Liverpool. Detailed recommendations for interactions with experimental COVID-19 therapies. Available from: https://www.covid19-druginteractions.org/

17. Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. MedRxiv 2020; DOI: 10.1101/2020.02.11.20021493. [Crossref]

18. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020; 200642. [Crossref]

19. Choo VWTC, Khoo MLG, Lee SF, Lai YC, Chin NM. Infection control measures for operative procedures in Severe Acute Respiratory Syndrome-related Patients. Anesthesiology 2004; 100: 1394-8. [Crossref]

20. Awad ME, Rumley JCL, Vazquez JA, Devine JG. Peri-operative considerations in urgent surgical care of suspected and confirmed COVID-19 orthopedic patients: operating rooms protocols and recommendations in the current COVID-19 pandemic. J Am Acad Orthop Surg 2020; DOI: 10.5435/JAAOS-D-20-00227. [Crossref]

21. Zhong Q, Liu YY, Lao Q, Zou YF, Jiang HX, Li H, et al. Spinal anesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: retrospective, single-centre, observational cohort study. Br J Anaesth 2020; 124: 670-5. [Crossref]

22. Li W, Huang J, Guo X, Zhao J, Mandell MS. Anesthesia management and perioperative infection control in patients with the novel coronavirus. J Cardiothorac Vasc Anesth 2020; DOI: 10.1053/j.jvca.2020.03.035. [Crossref]

23. Uppal V, Sondekoppam RV, Lobo CA, Kolli S, Kalagara HKP. Practice recommendations on neuraxial anesthesia and peripheral blocks during the COVID-19 pandemic. A joint statement by the American Society of Regional Anesthesia and Pain Medicine (ASRA) and European Society of Regional Anesthesia and Pain Therapy (ESRA). Available from: https://esraeurope.org/wp-content/uploads/2020/04/ESRAASRA-COVID-19-Guidelines.pdf. [Crossref]

24. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020; 382: 1564-7. [Crossref]

25. Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological complications of coronavirus disease (covid 19): encephalopathy. Cureus 2020; 12: e7352. [Crossref]

26. Bauer M, Bernstein K, Dinges E, Delgado C, El-Shara N, Sultan P, et al. Obstetric anesthesia during the COVID-19 pandemic. Anesth Analg 2020; DOI: 10.1213/ANE.0000000000004856. [Crossref]

27. Raineri SM, Cortegiani A, Accurso G, Procaccianti C, Vitale F, Caruso S, et al. Efficacy and Safety of Using High-Flow Nasal Oxygenation in Patients Undergoing Rapid Sequence Intubation. Turk J Anaesthesiol Reanim 2017; 45: 353-9. [Crossref]

28. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J 2020; 55: 2000892. [Crossref]

29. Available from: https://sites.google.com/view/aerosolbox/design?authuser=0
30. Greenland JR, Michelow MD, Wang L, London MJ. COVID-19 Infection: Implications for Perioperative and Critical Care Physicians. Anesthesiology 2020; 132: 1346-61. [Crossref]
31. Aminnejad R, Salimi A, Saeidi M. Lidocaine during intubation and extubation in patients with coronavirus disease (COVID-19). Can J Anaesth 2020; 67: 759. [Crossref]
32. Alp E, Bijl D, Bleichrodt RP, Hansson B, Voss A. Surgical smoke and infection control. J Hosp Infect 2006; 62: 1-5. [Crossref]
33. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronavirus and Blood Safety. Transfus Med Rev 2020; DOI: 10.1016/j.tmrv.2020.02.003. [Crossref]
34. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19 does not lead to a “Typical” Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 2020; 201: 1299-300. [Crossref]
35. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi, L, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med 2020; 1-4. [Crossref]
36. Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med 2020; 46: 854-87. [Crossref]
37. Geller C, Varbanov M, Duval RE. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses 2012; 4: 3044-68. [Crossref]